1. N 6 -Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation.
- Author
-
Cheng Y, Xie W, Pickering BF, Chu KL, Savino AM, Yang X, Luo H, Nguyen DT, Mo S, Barin E, Velleca A, Rohwetter TM, Patel DJ, Jaffrey SR, and Kharas MG
- Subjects
- Adenosine chemistry, Adenosine metabolism, Animals, Apoptosis, Cell Differentiation, Cell Nucleus genetics, Cell Proliferation, Female, Hematopoiesis, Humans, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute pathology, Liquid-Liquid Extraction, Mice, Mice, Inbred NOD, Mice, SCID, Nerve Tissue Proteins genetics, Phase Transition, Proto-Oncogene Proteins c-myc genetics, RNA Splicing Factors genetics, RNA Stability, RNA, Messenger chemistry, RNA, Messenger genetics, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Adenosine analogs & derivatives, Cell Nucleus metabolism, DNA Methylation, Leukemia, Myeloid, Acute prevention & control, Nerve Tissue Proteins metabolism, Proto-Oncogene Proteins c-myc metabolism, RNA Splicing Factors metabolism, RNA, Messenger metabolism
- Abstract
N
6 -Methyladenosine (m6 A) on mRNAs mediates different biological processes and its dysregulation contributes to tumorigenesis. How m6 A dictates its diverse molecular and cellular effects in leukemias remains unknown. We found that YTHDC1 is the essential m6 A reader in myeloid leukemia from a genome-wide CRISPR screen and that m6 A is required for YTHDC1 to undergo liquid-liquid phase separation and form nuclear YTHDC1-m6 A condensates (nYACs). The number of nYACs increases in acute myeloid leukemia (AML) cells compared with normal hematopoietic stem and progenitor cells. AML cells require the nYACs to maintain cell survival and the undifferentiated state that is critical for leukemia maintenance. Furthermore, nYACs enable YTHDC1 to protect m6 A-mRNAs from the PAXT complex and exosome-associated RNA degradation. Collectively, m6 A is required for the formation of a nuclear body mediated by phase separation that maintains mRNA stability and control cancer cell survival and differentiation., Competing Interests: Declaration of interests S.R.J. is a scientific founder of Gotham Therapeutics and has equity in this company. D. J. P. is a consultant for Ventus Therapeutics. M.G.K. is a consultant for Accent Therapeutics and M.G.K.’s laboratory receives some financial support from 28-7. These disclosures are not directly related to these studies. There is a patent pending., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF